Prilenia partners with Ferrer to advance pridopidine for ALS
Prilenia Therapeutics has entered a collaboration and license agreement with Ferrer to codevelop and commercialize pridopidine, its…
Articles by Andrea Lobo, PhD
Trial will use digital biomarkers to assess short-term ALS progression
Verge Genomics has identified multiple digital clinical biomarkers that can be used to assess short-term disease progression in the…
ALS patient treated with TRE-515 in expanded access program
A patient with late-stage amyotrophic lateral sclerosis (ALS) was treated with TRE-515, Trethera’s investigational therapy, under a U.S.
FDA approves study of SNUG01 gene therapy for ALS patients
The U.S. Food and Drug Administration (FDA) has authorized Sineugene Therapeutics to begin a Phase 1/2a trial of its…
Californians can help fund ALS research through tax contributions
People living in California can help fund amyotrophic lateral sclerosis (ALS) research when filing their state taxes. The…
Walk to Defeat ALS marks 25 years of fundraising event in US
The ALS Association’s Walk to Defeat ALS fundraising event this year is marking 25 years of bringing together people…
ALS Association tool aims to help patients navigate insurance issues
The ALS Association has launched a free resource to help people with amyotrophic lateral sclerosis (ALS) and their…
US trial of noninvasive ALS device gets green light to enroll patients
A clinical trial that will test a noninvasive, nerve-modulating device called MyoRegulator — designed to slow disease progression in…
Neuropeutics partners to advance potential disease-modifying therapy
Neuropeutics has partnered with LifeArc to advance work on a small molecule therapy against TDP-43 clumping…
iPSC-derived microglia may help advance ALS research, therapies
Ncardia has launched a stem cell-derived model of human microglia to advance research into neurodegenerative disorders such as amyotrophic…